Genomically stable gastric cancers (GCs) are enriched for the diffuse phenotype and hotspot mutations of RHOA. Here we aimed to validate the occurrence, phenotype and clinicopathological characteristics of RHOA mutant GCs in an independent Central European GC cohort consisting of 415 patients. The RHOA genotype (exon 2 and 3) was correlated with various genotypic, phenotypic and clinicopathological patient characteristics. Sixteen (3.9%) tumours had a RHOA mutation including four hitherto unreported mutations, that is, p.G17Efs*24, p.V24F, p.T37A and p.L69R. RHOA mutation was more prevalent in women (5.4% vs 2.8%), distal GCs (4.5% vs 2.4%), in poorly differentiated GCs (G3/G4; 4.8% vs 1.1%), T1/T2 tumours (6.2% vs 3.1%) and lacked distant metastases. Nine RHOA mutant GCs had a diffuse, four an intestinal, two an unclassified and one a mixed Laurén phenotype. KRAS and RHOA mutations were mutually exclusive. A single case showed both a RHOA and a PIK3CA mutation. No significant difference was found in the overall survival between RHOA mutant and wildtype GCs. Our study confirms the occurrence and clinicopathological characteristics of RHOA hotspot mutations in an independent patient cohort. However, we found no evidence for a prognostic or growth advantageous effect of RHOA mutations in GC.
- GASTRIC CANCER
- GASTRIC PATHOLOGY
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Statistics from Altmetric.com
Gastric cancer (GC) is the second leading cause of cancer-related deaths in men and women.1 ,2 Most patients are diagnosed with advanced stage disease with lymph node metastases already present, leading to a poor prognosis.3 ,4 Treatment options in patients with advanced GC are limited, but perioperative, adjuvant and palliative chemotherapy improves progression-free and overall survival.5–7 Evidence is accumulating that patient prognosis and treatment response does not only depend on tumour stage but also on specific genotypic and phenotypic tumour characteristics. The advancements of targeted therapy provide compelling evidence that cancers of the same anatomic origin, for example, lung or colon, show great variability in their response rates to chemotherapies, necessitating a more in-depth phenotypic/genotypic classification before treatment. Recently, whole-genome sequencing and comprehensive molecular profiling of GC found subtype-specific genetic and epigenetic alterations with unique mutational signatures.8 ,9 A molecular classification of GC was proposed, which categorises four subtypes: Epstein–Barr virus (EBV)-positive, microsatellite instable (MSI), chromosomal instable and genomically stable GCs.8 Genomically stable GCs are enriched for the diffuse phenotype and hotspot mutations of RHOA.9 ,10 Rho GTPases are small GTP/GDP-binding proteins that are found in all eukaryotes11 and act as molecular switches by cycling from GTP-bound active to GDP-bound inactive state. Cycling is controlled by guanine nucleotide-exchange factors, the intrinsic GTPase activity, GTPase activating proteins and guanine nucleotide-dissociation inhibitors.12 Rho GTPases play fundamental roles in cell migration, adhesion, cell survival, cell division, gene expression and vesicle trafficking,13 and hence, tumour cell biology.14 Interestingly, Rho/Rho-kinase inhibitors have been explored as putative therapeutic targets in diverse diseases.15 In this study, we aimed to validate independently the prevalence and clinicopathological characteristics of RHOA mutant GCs in a Central European patient cohort.
Materials and methods
From our archive, we retrieved patients who had undergone total or partial gastrectomy for adenocarcinomas of the stomach or esophagogastric junction. The patient characteristics are summarised in table 1. Date of patient death was obtained from the Epidemiological Cancer Registry of the state of Schleswig-Holstein, Germany. Follow-up data were retrieved from hospital records and general practitioners.
Study inclusion and exclusion criteria
Patients were included when (1) histology confirmed an adenocarcinoma and (2) the date of death or survival data were available. Patients were excluded when (1) histology identified a tumour type other than adenocarcinoma, (2) patients had previously undergone a resection of a Billroth-II stomach with cancer in the gastric remnant, (3) date of patient death or survival data had not been recorded and (4) perioperative chemotherapy was administered.
Histology and TNM classification
Tissue samples had been fixed in formalin and embedded in paraffin (FFPE). Sections were stained with H&E. Tumours were classified according to Laurén.16 Pathological tumour, node, metastases (pTNM) stage was determined according to the seventh edition of the Union for International Cancer Control UICC guidelines.17 Tissue micro arrays were generated as described previously.18
DNA sequence analysis
Genomic DNA was extracted from FFPE tissue using the QIAamp DNA mini kit (Qiagen, Hilden, Germany) following the manufacturer's instructions. Tissue sections were manually microdissected prior to DNA isolation to enrich tumour cells (>80%). For mutational analysis of exon 2 and 3 of RHOA, a 282 and 215 bp fragment were amplified by PCR using the primers 5′-caggaaacagctatgacagctctaattctctacatgctcc-3′ (sense) and 5′-gtaaaacgacggccagtcctatgacttcttgtgcattgc-3′ (antisense) for exon 2 and the primers 5′-gtaaaacgacggccagtactagctacacaggcagtgacaa-3′ (sense) and 5′-caggaaacagctatgacgtggggggattaaccttgca-3′ (antisense) for exon 3 (universal M13 sequencing primer binding sites were added to the 5′-end of the PCR primers). PCR products were purified using the QIAquick 96 PCR Purification Kit (Qiagen, Hilden, Germany) and sequenced by dye terminator cycle sequencing (BigDye Terminator v1.1 Cycle Sequencing kit, Applied Biosystems, Darmstadt, Germany) with universal M13 primers. The sequencing products were purified using the DyeEx 96 Kit (Qiagen) and analysed on a Genetic Analyzer 3500 (Applied Biosystems).
Assessment of phenotype, genotype and infectious status
The KRAS- (codon 12 and 13), PIK3CA- (exon 9 and 20) genotype, the mucine-, E-cadherin- and β-catenin-immunophenotype, as well as the Helicobacter pylori, Epstein–Barr virus, microsatellite and Her2/neu status were assessed as described in detail previously (see online supplementary materials and methods).18 ,19
Statistical analyses were performed using SPSS V.20.0 (IBM Corporation). For continuous variables, cases were divided into two groups by splitting at the median value. Median overall survival was determined using the Kaplan–Meier method, and the log-rank test was used to determine significance. For comparison purposes, the median survival time, its SD and 95% CI were calculated. The significance of correlation between clinicopathological variables was tested using Fisher’s exact test. For variables of ordinal scale (T-category, N-category, tumour stage), we applied Kendall’s tau test instead. A p≤0.05 was considered statistically significant. The p values are given unadjusted.
A total of 415 patients fulfilled all study criteria, including 249 (60.0%) men and 166 women (40.0%; table 1). The median patient age was 68 years. According to Laurén, an intestinal-type GC was found in 210 (50.6%), a diffuse type in 134 (32.3%), a mixed type in 27 (6.5%) and an unclassifiable type in 41 (9.9%) patients. According to the mucin-phenotype, 102 (27.9%) GCs were of the intestinal, 57 (15.6%) of the gastric, 146 (37.3%) of the mixed and 60 (16.4%) of the unclassified type (table 1). In total, 202 (52.6%) GCs were categorised as lysozyme-positive, and 280 (73.3%) as E-cadherin-negative and 213 (55.5%) as β-catenin-negative. Non-neoplastic mucosa was available from 351 patients and was screened for H. pylori. Fifty-three (15.1%) patients had a persistent infection with H. pylori. EBV-RNA was found in 15 (3.7% of 402 valid results) GCs.
Prevalence of RHOA mutation
Sixteen (3.9%) tumours had an RHOA mutation in exon 2 (12 (75%); p.R5Q, p.G17E, p.G17Efs*24, p.L22R, p.V24F, p.T37A and p.Y42C) or 3 (4 (25%); p.L57V and p.L69R) (table 2). Fourteen tumours had a single-point mutation and two harboured a deletion/insertion mutation. A transition (A>G or G>A) was found in nine cases, which was restricted to exon 2. A transversion (G>T or T>G) was present in five cases being more prevalent in exon 3 (table 2).
Correlation of RHOA mutation with clinicopathological patient characteristics
RHOA mutation was more prevalent in women (5.4% vs 2.8%), distal GCs (4.5% vs 2.4%) and in poorly differentiated GCs (G3/G4; 4.8% vs 1.1%). Interestingly, RHOA mutant GCs usually showed a lower T-category. However, neither of these findings was statistically significant (table 1).
According to Laurén, nine (56%) RHOA mutant GCs had a diffuse, four (25%) an intestinal, two (13%) an unclassified and one (6%) a mixed phenotype (figure 1). RHOA mutant GCs were most commonly lysozyme-immunopositive (80%), and E-cadherin-immunonegative (80%) and β-catenin- (73%) immunonegative. KRAS and RHOA mutations were mutually exclusive. A single case showed both a RHOA and a PIK3CA mutation. MSI and EBV were found each in a single case with RHOA mutation.
No significant difference was found in the overall survival between RHOA mutant and wildtype GCs (figure 2).
Hitherto, oncological treatment of malignant epithelial tumours largely depended on their anatomical origin. With the advancements of targeted therapy, it became increasingly evident that cancers of the same anatomical origin show great variability in their response rates to chemotherapies, necessitating a more in-depth phenotypic/genotypic classification prior to treatment. While this has led to major improvements in few cancer types, it is still in its infancies in GC. Except for HER2 status, no other molecular (ie, diagnostic, prognostic or predictive) classifier has reached clinical practice despite evidence that response to chemotherapy may depend on genotypical/phenotypical characteristics of GC: using gene expression profiling, Tan et al20 identified intrinsic subtypes of GC (intestinal vs diffuse type) that respond differently to 5-fluouracil, cisplatin and oxaliplatin. Recently, whole-genome sequencing and comprehensive molecular profiling proposed four molecular subtypes of GC,8 of which the genomically stable subtype was specifically enriched for the diffuse phenotype and hotspot mutations of RHOA.9 ,10
Here we aimed to validate the occurrence, phenotype and clinicopathological characteristics of RHOA mutant GCs in an independent Central European GC cohort. Sixteen (3.9%) tumours of our cohort had a RHOA mutation. The prevalences reported hitherto ranged from 6%8 ,10 to 25.3%9 and largely depend on the composition of the cohorts, being higher in cohorts with a greater number of diffuse-type GCs. As yet, our study comprises the only single-centre GC cohort tested for RHOA mutation and the largest GC patient series: The Cancer Genome Atlas Research Network8 studied 295 patients, Wang et al10 100 patients and Kakiuchi et al9 87 patients. Five mutations of our cohort had been described previously, that is, p.R5Q, p.G17E, p.L22R, p.Y42C, p.L57 and p.L69R.8–10 However, we also found mutations hitherto unreported in GC including a deletion-insertion mutation in exon 2, that is, p.G17Efs*24, p.V24F and p.T37A (table 2). The mutations affect the functional domains of RHOA, such as the GTP-binding sites and the effector binding region and may have different effects.8–10 p.Tyr42Cys and p.Gly17Glu were considered as gain-of-function mutations, which may provide strong growth advantage in diffuse-type GC progression.9 To the contrary, Wang et al10 provided evidence that p.Tyr42Cys and p.Leu57Val lead to defective signalling, promoting escape from anoikis. In order to support any of these contentions, we correlated the presence of RHOA mutations with various clinicopathological patient characteristics. In accordance with previous observations, RHOA mutation was more prevalent in women, distal GCs and in poorly differentiated GCs.10 Interestingly, RHOA mutant GCs usually showed a lower T-category and no distant metastases, seemingly contradicting a growth advantageous effect. However, neither of these findings was significant (table 1) and larger patient cohorts may be needed to demonstrate a putative effect on local tumour growth or tumour spread.
Previously, Tan et al20 described 171 genes, which separate intestinal-type from diffuse-type GC. Lysozyme was among the genes highly significantly differentially expressed and was selected by us as another putative immunohistochemical marker between intestinal-type and diffuse-type GC.20 While lysozyme expression correlated significantly with RHOA genotype, immunostaining, in general, was unsuitable to detect RHOA mutant GCs as only a small proportion of E-cadherin-immunonegative /β-catenin-immunonegative and lysozyme-immunopositive GCs harboured RHOA mutations (<6%; table 1).
Rho GTPases have been associated with the alterations of P53, KRAS and APC, as well as KRAS/PIK3CA-signalling in colon cancer, lung cancer and liver carcinogenesis.14 ,21–23 Therefore, we were interested to compare the RHOA genotype with other genetic alterations found previously in our cohort18: KRAS and RHOA mutations were mutually exclusive, lending support to the hypothesis that the KRAS–RHOA axis may be a putative signalling axis in GC as it has recently been shown in non-small cell lung cancer.22 A single case showed both an RHOA and a PIK3CA mutation. However, the overall prevalences of KRAS, PIK3CA and RHOA mutations are low in our GC cohort (each below 5%) and no firm conclusions can be drawn.
The whole-genome sequencing and comprehensive molecular profiling classified EBV-positive and MSI GCs as distinct molecular subtypes. Interestingly, MSI and EBV were found each in a single case with RHOA mutation. Similar findings were made by others: a minority of RHOA-mutant GCs can be MSI or EBV-positive.8–10 Thus, molecular subtypes may overlap in a single patient. However, the vast majority of RHOA mutant GCs was microsatellite stable (93%) and EBV-negative (94%), confirming previous findings.8–10 No significant difference was found in the overall survival between RHOA mutant and wildtype GCs (figure 2), again raising doubt about a significant effect on tumour progression. In this respect, it is interesting to note that 17 patients of our cohort, commonly showing an intestinal-type GC, carried a KRAS mutation.18 Thus, RHOA and KRAS mutation are not only mutually exclusive but are linked also to different phenotypes. In summary, our study confirms the occurrence and clinicopathological characteristics of RHOA hotspot mutations in an independent Central European patient cohort. Currently, we cannot confirm the prognostic or growth advantageous effect of RHOA mutations in GC and further studies into this topic are warranted.
Take home messages
RHOA hotspot mutations are rare and diverse in gastric cancer.
RHOA mutations are more prevalent in women, distal and poorly differentiated gastric cancers.
No significant difference was found in the overall survival between RHOA mutant and wildtype gastric cancers.
RHOA- and KRAS mutations are mutually exclusive. RHOA mutations may occur occasionally in microsatellite instable or Epstein-Barr-virus-positive gastric cancers.
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
- Data supplement 1 - Online supplement
Abstract in German
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
- Abstract in German - Online abstract
Handling editor Cheok Soon Lee
Contributors Study concept and design: CR and SK. Acquisition of surgical pathological data: CR, CB and SK. Analysis and interpretation of data: CR and H-MB. Drafting of the manuscript and critical revision of the manuscript for important intellectual content: all authors. Obtained funding: CR. Administrative, technical or material support: CR and SK. Study supervision: CR.
Funding CR is supported by grants of the German Research Foundation (grant no. Ro 1173/11 and Ro 1173/12).
Competing interests None declared.
Ethics approval Ethics committee of the University Hospital Schleswig-Holstein, Campus Kiel (reference number D 453/10).
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.